In a crucial part of the European Patients’ Academy (EUPATI) strategy, 47 patients and patient representatives from across Europe are meeting this week in Barcelona, Spain, to continue their 13-month online training course to become expert patients in the medicines development process.
In a crucial part of the European Patients’ Academy (EUPATI) strategy, 47 patients and patient representatives from across Europe are meeting this week in Barcelona, Spain, to continue their 13-month online training course to become expert patients in the medicines development process.
According to EUPATI Director Jan Geissler of Germany, a chronic myeloid leukemia patient and engaged patient advocate, “The EUPATI Expert Patient Training Course is one of the very first tangible results of our project. At this first face-to-face meeting of our course, we are looking forward to learning as much from our students as what we will be teaching to them.”
The concept is to equip patient advocates with information and tools to understand how the medicines development process works, and motivate them to become more involved in it to make sure research is truly centered around their needs. This five-day meeting is the first of two to be held this year.
The themes under discussion will include the process of development of new medicines and research from the bench to post-marketing, personalized and predictive medicines, and the safety and risk:benefit ratio of drugs. Some six months from now, these same 47 students will be returning to talk about and learn more on pharmacoeconomics, health economics, designing clinical trials, and the roles of patients in that design.
“This will enable them to work on designing clinical studies, give counsel and feedback to existing protocols from academic and commercial sponsors, as well as to regulatory authorities nationally and at the European Medicines Agency in London. This all will raise the bar of what a patient advocate is and what a patient advocate can be,” wrote EUPATI in a statement.
Although we have been working with the students online for 6 months and ironing out details and concerns as we go along, this is the first time both we as a project and they as the students will be interacting directly, explained Per Spindler, Director at Biopeople, University of Copenhagen, Denmark.
EUPATI aims to engage with more than 100,000 Europeans via its Internet Library, which will come online towards the end of 2015 and will be available in English, French, Spanish, Italian, German, Polish and Russian.
For full details about the participants in the training program, click here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.